OptiBiotix Health’s Stephen O’Hara discusses their new development agreement with Royal DSM in this exclusive interview with DirectorsTalk
Stephen O’Hara, CEO of OptiBiotix LON:OPTI, commented: “We are really pleased with the results of this study which opens up opportunities for a single product for both conditions (high cholesterol and high blood pressure) or two
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara caught up with DirectorsTalk to talk about the JV with DSM. Stephen expands on the agreement details, explains the types of products involved
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk that it has entered into a joint development agreement with Royal DSM. The agreement allows for collaboration between both parties to develop new products using OptiBiotix’s OptiBiotic® technology platform.
OptiBiotix Health Plc (LON:OPTI) CEO Stephen OHara commented on new report published Thursday that shows that more than one in 10 men and one in seven women are obese. Worldwide obesity
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has said to DirectorsTalk that further to the announcement made 9 July 2015
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk this morning that it has acquired the exclusive rights
OptiBiotix Health plc (LON:OPTI) presented at the 2nd Microbiome R&D and Business Collaboration Congress: Asia, part of Global Engage’s worldwide microbiome series. The conference was attended by over 180 leading
The White House Office of Science and Technology Policy (OSTP) have recently made a national call to action for new public and private commitments to support microbiome science. “The need
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
